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Abstract
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CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic
antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and
desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine,
doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19
genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical
Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19
Genotypes and Dosing of Tricyclic Antidepressants.

Keywords
CYP2D6; CYP2C19; pharmacogenetics; tricyclic antidepressants; amitriptyline; clomipramine;
desipramine; doxepin; imipramine; nortriptyline; and trimipramine

INTRODUCTION
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Observed inter-individual differences in tricyclic antidepressant (TCA) pharmacokinetic
parameters and treatment outcomes are associated with CYP2D6 and/or CYP2C19 genetic
variation. The purpose of this guideline is to provide information to allow the interpretation
of existing CYP2D6 and/or CYP2C19 genotyping results to guide TCA dosing and
selection. Other clinical variables that may influence TCA therapy as well as genotyping
cost-effectiveness are beyond the scope of this document. CPIC guidelines are periodically
updated at https://cpicpgx.org/guidelines/ and http://www.pharmgkb.org.

FOCUSED LITERATURE REVIEW
A systematic literature review focused on CYP2D6 and CYP2C19 genetic variations and
their relevance to gene-based dosing of TCAs was conducted (see Supplementary Data
online). This guideline was developed based on interpretation of the literature by the authors
and by experts in the field.

GENES: CYP2D6 AND CYP2C19
Author Manuscript

CYP2D6 background
The CYP2D6 gene is highly polymorphic. Over 100 known allelic variants and subvariants
have been identified, and there are substantial ethnic differences in observed allele
frequencies (CYP2D6 Allele Definition Table and CYP2D6 Frequency Table (1)). The most
commonly reported alleles are categorized into functional groups as follows: normal
function (e.g., CYP2D6*1 and *2), decreased function (e.g., CYP2D6*9, *10, and *41), and
no function (e.g., CYP2D6*3-*6) (2, 3). Because CYP2D6 is subject to deletions or
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duplications, many clinical laboratories also report copy number. Deletions are indicated by
the CYP2D6*5 allele, and gene duplications are denoted by an “xN” following the allele
(e.g., CYP2D6*1xN, where xN represents the number of CYP2D6 gene copies).
CYP2C19 background

Author Manuscript

Similar to CYP2D6, the CYP2C19 gene is highly polymorphic; over 35 known allelic
variants and subvariants have been identified (3) (CYP2C19 Allele Definition Table (4)).
Although there are ethnic differences in allele frequencies (CYP2C19 Frequency Table (4)),
the majority of patients will carry a CYP2C19*1,*2,*3 or *17 allele (5). CYP2C19*1 is the
wild-type allele encoding a fully functional enzyme. CYP2C19*2-*8 are no function alleles
of which CYP2C19*2 is the most frequently observed, though CYP2C19*3 is more
common among individuals of Asian ancestry (3, 5). The CYP2C19*17 allele, defined by a
variant in the gene promoter region, causes enhanced gene transcription resulting in greater
metabolic capacity (6) and is therefore classified as an increased function allele.
Genetic test interpretation
Clinical laboratories usually interrogate for the more frequently observed CYP2D6 and
CYP2C19 genetic variants and translate the results into star-allele (*) nomenclature. Each
star-allele, or haplotype, is defined by a specific combination of single-nucleotide
polymorphisms and/or other genetic variants within the gene locus of either CYP2D6 or
CYP2C19 (5). Genetic test results are reported as the summary of inherited maternal and
paternal star-alleles referred to as a diplotype (e.g., CYP2D6*1/*2 and CYP2C19*1/*1).
The more frequently observed alleles and their functional status can be found in the
CYP2D6 (1) and CYP2C19 Allele Definition Tables (4).

Author Manuscript

Scoring systems have been developed in an attempt to provide a uniform approach to
quantitate the predicted functional status of CYP2D6 alleles as follows: 1 for normal
function, 0.5 for decreased function, and 0 for no function alleles (see Supplemental
Material; CYP2D6 Allele Definition Table (1)) (2, 7). The activity value for each allele of
the diplotype is totaled to provide a CYP2D6 activity score. If CYP2D6 gene duplications
are detected, the activity value of the duplicated allele is multiplied by the number of
duplications present before calculating the activity score (Table 1, Supplemental Tables S1
and S2). See the Supplement for further explanation.

Author Manuscript

Patients with two normal function CYP2C19 alleles are categorized as normal metabolizers
and individuals carrying one or two no function alleles are considered intermediate and poor
metabolizers, respectively (Table 1). Limited data suggest that CYP2C19*17 may not
compensate for no function alleles such as the CYP2C19*2 allele (8). Therefore, patients
carrying the CYP2C19*17 increased function allele in combination with a no function allele
are considered intermediate metabolizers. These phenotype assignments are analogous to the
CPIC guideline for selective serotonin reuptake inhibitors (3). See Supplement for
discussion regarding CYP2C19 rapid metabolizer phenotype.
Reference laboratories use varying methods to assign phenotypes. Before pharmacotherapy
modifications are made based upon this guideline, it is advisable to determine a patient’s
phenotype as described above.
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.
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Commercially available genetic testing options change over time. Additional information
about pharmacogenetic testing can be found at the Genetic Testing Registry website (http://
www.ncbi.nlm.nih.gov/gtr/).
Incidental findings
Independent of drug metabolism and response, there are currently no diseases or conditions
that have been convincingly linked to variants in the CYP2D6 or CYP2C19 genes (5, 7).

DRUGS: AMITRIPTYLINE AND NORTRIPTYLINE
Background

Author Manuscript
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Tricyclic antidepressants (TCAs) are mixed serotonin and norepinephrine reuptake inhibitors
used to treat several disease states including depression, obsessive-compulsive disorder, and
neuropathic pain in addition to migraine prophylaxis. The TCAs have similar but distinct
chemical structures referred to as tertiary and secondary amines. The pharmacological
properties of the tertiary and secondary amines differ, with tertiary amines having a more
pronounced serotonergic effect and secondary amines having a greater noradrenergic effect
(Supplemental Tables S3 and S4) (9, 10). The tertiary amines (e.g., amitriptyline) are mainly
metabolized by CYP2C19 to desmethyl-metabolites (Figure 1), also referred to as secondary
amines (e.g., nortriptyline). It should be noted that the desmethyl-metabolites nortriptyline
as well as desipramine are pharmacologically active with antidepressant properties as well as
with distinct clinical features that differ from the parent drugs amitriptyline and imipramine.
Both the tertiary and secondary amines are metabolized by CYP2D6 to less active hydroxymetabolites (Figure 1, Supplemental Table S3). CYP2C19 impacts the ratio of tertiary to
secondary amine plasma concentrations, but may have less influence on overall drug
clearance than CYP2D6 (11). Although the total concentration of amitriptyline and
nortriptyline may be unchanged for a CYP2C19 ultrarapid or poor metabolizer in certain
instances, an imbalance between serotonergic and noradrenergic affect could influence
clinical response or toxicities. There is limited evidence demonstrating that a serotonergic/
noradrenergic imbalance influences outcomes, thus contributing to the optional
recommendations in Table 3. Serotonin reuptake inhibition is expected to be more
pronounced in CYP2C19 poor metabolizers due to the decreased conversion of parent
tertiary amines to their respective metabolites (10).

Author Manuscript

The use of TCAs to treat psychiatric disorders has declined in part due to the occurrence of
undesirable side effects along with the growing availability of alternatives with more
acceptable side effect profiles. Although TCAs are still used to treat depression (12), they
are now more often used in the context of pain management (13, 14). Inter-individual
differences in side effects and treatment response have been associated with variability of
tricyclic plasma concentrations (15, 16). Patients may be predisposed to treatment failure or
adverse effects due to genetic variation in CYP2D6 altering drug clearance or in CYP2C19
altering the ratio of parent drug to metabolites. Common adverse effects include
anticholinergic, central nervous system and cardiac effects. Tertiary and secondary amines

Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.

Hicks et al.

Page 5

Author Manuscript

along with their metabolites each have unique side effect profiles as detailed in
Supplemental Table S4.
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Both amitriptyline and nortriptyline are used as representative TCAs for this guideline
because the majority of pharmacogenomic studies have focused on these two drugs.
However, the results of these studies may apply to other TCAs because these drugs have
comparable pharmacokinetic properties (15, 17). TCAs are well absorbed from the
gastrointestinal tract, and the average extent of first pass metabolism is approximately 50%,
although the average first pass metabolism of doxepin may be closer to 70% (15). The
clearance of TCAs is mostly a linear process, but saturation of the hydroxylation pathway
may occur at higher plasma concentrations for certain TCAs including imipramine and
desipramine (15, 18). Additionally, extrapolated dose adjustments based on metabolizer
status are similar across the tricyclic class (17). Because some studies investigating the
influence of CYP2D6 and/or CYP2C19 genotype/phenotype on the pharmacokinetics of
TCAs used a single dose, it should be noted that in this guideline tricyclic metabolism was
assumed to be similar after single or multiple dosing, and no differentiation was made
between evidence from single dose studies or from multiple dose studies (16).
Linking genetic variability to variability in drug-related phenotypes
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There is substantial evidence linking CYP2D6 and CYP2C19 genotypes to phenotypic
variability in tricyclic side effects and pharmacokinetic profiles. Modifying
pharmacotherapy for patients who have CYP2D6 or CYP2C19 genetic variants that affect
drug efficacy and safety could potentially improve clinical outcomes, and reduce the failure
rate of initial treatment. The application of a grading system to the evidence linking
CYP2D6 and CYP2C19 genotypic variations to phenotypic variability in the response to
amitriptyline or nortriptyline indicates a high quality of evidence in the majority of cases
(Supplemental Tables S5–S7). This body of evidence, rather than randomized clinical trials,
provides the basis for amitriptyline and nortriptyline dosing recommendations in Tables 2
and 3, respectively. Optimal therapeutic plasma concentrations for the TCAs have been
defined (19). CYP2D6 and CYP2C19 poor or ultrarapid metabolizers may have tricyclic
plasma concentrations outside the recommended therapeutic range, thus increasing the risk
of treatment failure or side effects (17, 20–22). TCA plasma concentrations have been
shown to be predictive of toxicity and efficacy, with guidelines defining therapeutic ranges
for TCAs (19). However, there are less data supporting a direct correlation between
genotype and response when compared to the correlation between genotype and plasma
concentrations. Some studies describe a relationship between genotype and response (23–
25) while other studies do not (26). Therefore, this guideline takes into consideration both
clinical outcomes and observed tricyclic plasma concentrations based on genotype/
phenotype characteristics.
Therapeutic recommendations
CYP2D6 dosing recommendations—For neuropathic pain treatment, where lower
initial doses of TCAs are used, gene-based dosing recommendations are found in the
subsection Gene-based dosing recommendations for neuropathic pain treatment. Table 2
summarizes the gene-based dosing recommendations for CYP2D6 and amitriptyline and
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nortriptyline for situations in which a higher initial dose is warranted, such as depression
treatment. The recommended starting dose of amitriptyline or nortriptyline does not need
adjustment for those with genotypes predictive of CYP2D6 normal metabolism. A 25%
reduction of the recommended dose may be considered for CYP2D6 intermediate
metabolizers (27). The strength of this recommendation is classified as “moderate” because
patients with a CYP2D6 activity score of 1.0 are inconsistently categorized as intermediate
or normal metabolizers in the literature, making these studies difficult to evaluate.

Author Manuscript

CYP2D6 ultrarapid metabolizers have a higher probability of failing amitriptyline or
nortriptyline pharmacotherapy due to subtherapeutic plasma concentrations, and alternate
agents are preferred. There are documented cases of CYP2D6 ultrarapid metabolizers
receiving large doses of nortriptyline in order to achieve therapeutic concentrations (22).
However, very high plasma concentrations of the nortriptyline hydroxy-metabolite were
present, which may increase the risk for cardiotoxicity. If a tricyclic is warranted, there are
insufficient data in the literature to calculate a starting dose for a patient with CYP2D6
ultrarapid metabolizer status, and therapeutic drug monitoring is strongly recommended.
Adverse effects are more likely in CYP2D6 poor metabolizers due to elevated tricyclic
plasma concentrations (28); therefore, alternate agents are preferred. If a tricyclic is
warranted, consider a 50% reduction of the usual dose, and therapeutic drug monitoring is
strongly recommended.

Author Manuscript

CYP2C19 dosing recommendations—Dosing recommendations for neuropathic pain
treatment with amitriptyline are found in the subsection Gene-based dosing
recommendations for neuropathic pain treatment. Table 3 summarizes the gene-based dosing
recommendations for CYP2C19 and amitriptyline when higher initial starting doses are
warranted. The usual starting dose of amitriptyline may be used in CYP2C19 normal and
intermediate metabolizers. Although CYP2C19 intermediate metabolizers would be
expected to have a modest increase in the ratio of amitriptyline to nortriptyline plasma
concentrations, the evidence does not indicate that CYP2C19 intermediate metabolizers
should receive an alternate dose.

Author Manuscript

Patients taking amitriptyline who are CYP2C19 rapid or ultrarapid metabolizers may be at
risk for having low plasma concentrations and an imbalance between parent drug and
metabolites causing treatment failure and/or adverse events. Although the CYP2C19*17
allele did not alter the sum of amitriptyline plus nortriptyline plasma concentrations, it was
associated with higher nortriptyline plasma concentrations, possibly increasing the risk of
adverse events (8). For patients taking amitriptyline, extrapolated pharmacokinetic data
suggest that CYP2C19 rapid or ultrarapid metabolizers may need a dose increase (17). Due
to the need for further studies investigating the clinical importance of CYP2C19*17
regarding tricyclic metabolism and the possibility of altered concentrations, we recommend
to consider an alternative tricyclic or other drug not affected by CYP2C19. This
recommendation is classified as optional due to limited available data. If amitriptyline is
administered to a CYP2C19 rapid or ultrarapid metabolizer, therapeutic drug monitoring is
recommended.

Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.

Hicks et al.

Page 7

Author Manuscript

CYP2C19 poor metabolizers are expected to have a greater ratio of amitriptyline to
nortriptyline plasma concentrations (29). The elevated amitriptyline plasma concentrations
may increase the chance of a patient experiencing side effects. Consider a 50% reduction of
the usual amitriptyline starting dose along with therapeutic drug monitoring (17).
Other TCAs—Because the TCAs have comparable pharmacokinetic properties, it may be
reasonable to extrapolate this guideline to other TCAs including clomipramine, desipramine,
doxepin, imipramine, and trimipramine (Tables 2 and 3; Supplemental Tables S8–S16), with
the acknowledgement that there are fewer data supporting dose adjustments for these drugs
than for amitriptyline or nortriptyline.
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CYP2D6 and CYP2C19 combined dosing recommendations—Although specific
combinations of CYP2D6 and CYP2C19 alleles are likely to result in additive effects on the
pharmacokinetic properties of TCAs, little information is available on how to adjust initial
doses based on combined genotype information. Patients carrying at least one CYP2D6 no
function allele and two CYP2C19 normal function alleles had an increased risk of
experiencing side effects when administered amitriptyline, while patients with at least one
CYP2C19 no function allele and two CYP2D6 normal function alleles had a lower risk of
experiencing side effects (22, 30). Combinatorial gene-based recommendations are provided
in Table 4. Therapeutic drug monitoring may be advised if a tricyclic is prescribed to a
patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with
CYP2C19 ultrarapid, rapid, intermediate or poor metabolism. There are sparse data in
patients with a combinatorial CYP2C19 ultrarapid/rapid/intermediate/poor metabolizer
phenotype and CYP2D6 ultrarapid/intermediate/poor phenotype. Because there are limited
clinical or pharmacokinetic data regarding these combinatorial phenotypes,
pharmacotherapy recommendations are classified as optional.
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Gene-based dosing recommendations for neuropathic pain treatment—
Amitriptyline is often used at lower dosages (e.g., 0.1 mg/kg/day in pediatric patients; initial
doses of 25 mg daily may be prescribed to adults) for treatment of neuropathic pain
compared to treatment for depressive disorders (13, 14). Because of the lower dosage, it is
less likely that CYP2D6 or CYP2C19 poor or intermediate metabolizers will experience
adverse effects due to supratherapeutic plasma concentrations of amitriptyline (31).
Therefore, we recommend no dose modifications for poor or intermediate metabolizers
when prescribed amitriptyline at a lower dose for treatment of neuropathic pain, but these
patients should be monitored closely for side effects. If larger doses of amitriptyline are
warranted, we recommend following the gene-based dosing guidelines presented in Tables
2–4.
There are limited data to support dose recommendations for CYP2C19*17 carriers who are
prescribed amitriptyline at lower doses for neuropathic pain treatment. There are also little
data describing the use of amitriptyline for neuropathic pain in CYP2D6 ultrarapid
metabolizers. Based on predicted and observed pharmacokinetic data in those with
depression, CYP2D6 ultrarapid metabolizers may be at an increased risk of failing
amitriptyline therapy for neuropathic pain due to lower than expected drug concentrations,
and thus alternative agents should be considered (32). Although there is sparse information
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.
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on how to adjust initial amitriptyline doses based on combined CYP2D6 and CYP2C19
genetic results when treating neuropathic pain, caution should be used when patients have a
combination of poor or ultrarapid phenotypes (e.g., a CYP2D6 poor metabolizer also having
CYP2C19 ultrarapid or poor metabolism).
Pediatrics—There are scarce studies focusing solely on CYP2D6 or CYP2C19 genotype
and association with pharmacokinetic parameters or treatment outcomes of TCAs in
pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19
activity may be increased in children relative to adults (3). Although further genomic
ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot
be extrapolated to pediatric patients.
Other considerations

Author Manuscript

Consideration of drug interactions and patient characteristics—Patients treated
for psychiatric disorders often require multiple medications, which can influence tricyclic
plasma concentrations, side effects, and therapeutic failure (15). Recent data indicate that up
to 20% of patients treated for depression may be converted to CYP2D6 poor metabolizer
status (33). For example, patients taking amitriptyline in combination with a potent CYP2D6
inhibitor, such as fluoxetine, may have dramatic increases in amitriptyline plasma
concentrations (34). It has been suggested that patients taking strong CYP2D6 inhibitors
should be treated similarly to CYP2D6 poor metabolizers (7). Additionally, patients with
increased age, liver disease, and reduced renal function may require reduced doses of TCAs
(15). Drug-drug interactions along with patient characteristics should be considered in
addition to the gene-based dosing recommendations presented herein.

Author Manuscript

Minor metabolic pathways of TCAs—Other cytochrome P450 enzymes including
CYP3A4 and CYP1A2 metabolize TCAs to a lesser extent (15, 31, 35, 36). There is
currently no strong evidence supporting gene-based dosing recommendations for other CYP
enzymes that metabolize TCAs.
Implementation of this guideline—The guideline supplement contains resources that
can be used within electronic health records (EHRs) to assist clinicians in applying genetic
information to patient care for the purpose of drug therapy optimization (see Resources to

incorporate pharmacogenetics into an electronic health record with clinical decision support
sections of supplement.).

POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
Author Manuscript

For patients who have existing CYP2D6 and/or CYP2C19 genotyping test results, the
potential benefit is identifying those patients who are at an elevated risk of experiencing side
effects or therapeutic failure. For those patients, dose adjustments can be made or an
alternative agent selected. A limitation inherent to most commercially available genotyping
tests is that rare or de novo variants are not detected. Additionally, some alleles are not well
characterized resulting in uncertainty when predicting the phenotype from some genetic test
results. Genotyping is reliable when performed in qualified clinical laboratories, but as with
any laboratory test, an error can occur. Any errors in genotyping or phenotype prediction,
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.
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along with the presence of a rare genomic variant not tested for, could potentially have
lifelong implications for the patient’s drug therapy.

CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC
TESTS
The application of genotype-based dosing is most appropriate when initiating therapy with a
tricyclic. Obtaining a pharmacogenetic test after months of drug therapy may be less helpful
in some instances, as the drug dose may have already been adjusted based on plasma
concentrations, response, or side effects. Similar to all diagnostic tests, genetic tests are one
of several pieces of clinical information that should be considered before initiating drug
therapy.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation
Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. This work
was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374).
EDK is supported by R01 GM63674 and R01 DA14211. TCS is supported by R01 GM088076 and the Agency for
Healthcare Research and Quality (R01 HS19818-01). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the Agency for Healthcare Research and Quality. VLE is
supported by the NIMH (R01 MH082784). DJM is supported by a New Investigator Salary Award from the
Canadian Institutes of Health Research, a New Investigator Fellowship Award from the Ontario Mental Health
Foundation and an Early Researcher Award by the Ministry of Research and Innovation of Ontario. AG is supported
by R01 GM088076-05.

Author Manuscript

References

Author Manuscript

1. [Accessed September 16 2016] PGx Gene-specific Information Tables for CYP2D6. <https://
www.pharmgkb.org/page/cyp2d6RefMaterials>
2. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity
score: translating genotype information into a qualitative measure of phenotype. Clinical
pharmacology and therapeutics. 2008; 83:234–42. [PubMed: 17971818]
3. Hicks JK, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for
CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical
pharmacology and therapeutics. 2015; 98:127–34. [PubMed: 25974703]
4. [Accessed September 16 2016] PGx Gene-specific Information Tables for CYP2C19. <https://
www.pharmgkb.org/page/cyp2c19RefMaterials>
5. Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome
P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical pharmacology and therapeutics.
2011; 90:328–32. [PubMed: 21716271]
6. Sim SC, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant
for the drug response to proton pump inhibitors and antidepressants. Clinical pharmacology and
therapeutics. 2006; 79:103–13. [PubMed: 16413245]
7. Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for
codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical
pharmacology and therapeutics. 2012; 91:321–6. [PubMed: 22205192]

Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.

Hicks et al.

Page 10

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

8. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of
amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. The pharmacogenomics
journal. 2011; 11:359–67. [PubMed: 20531370]
9. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.
British journal of pharmacology. 2007; 151:737–48. [PubMed: 17471183]
10. Shimoda K, Jerling M, Bottiger Y, Yasuda S, Morita S, Bertilsson L. Pronounced differences in the
dispositon of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol.
1999; 19:393–400. [PubMed: 10505580]
11. Jiang ZP, et al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J
Clin Pharmacol. 2002; 58:109–13. [PubMed: 12012142]
12. Association, A.P. Practice Guideline for the Treatment of Patients With Major Depressive Disorder.
3. American Psychiatric Publishing; Arlington, VA: 2010.
13. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. The Clinical journal of
pain. 2000; 16:S49–55. [PubMed: 10870740]
14. Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer
pain. European journal of cancer. 2008; 44:1078–82. [PubMed: 18439818]
15. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cellular and molecular
neurobiology. 1999; 19:373–409. [PubMed: 10319193]
16. Potter WZ, Zavadil AP 3rd, Kopin IJ, Goodwin FK. Single-dose kinetics predict steady-state
concentrations on imipramine and desipramine. Archives of general psychiatry. 1980; 37:314–20.
[PubMed: 7362419]
17. Stingl JC, Brockmoller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual
impact on psychiatric therapy and regulation of brain function. Molecular psychiatry. 2012
18. Cooke RG, Warsh JJ, Stancer HC, Reed KL, Persad E. The nonlinear kinetics of desipramine and
2-hydroxydesipramine in plasma. Clinical pharmacology and therapeutics. 1984; 36:343–9.
[PubMed: 6467794]
19. Hiemke C, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry:
Update 2011. Pharmacopsychiatry. 2011; 44:195–235.
20. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in
white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clinical pharmacology and
therapeutics. 1998; 63:444–52. [PubMed: 9585799]
21. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug
metabolizing enzymes. Biochimica et biophysica acta. 2007; 1770:489–94. [PubMed: 17113714]
22. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of
debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic
antidepressants. Therapeutic drug monitoring. 1985; 7:478–80. [PubMed: 4082245]
23. Bertilsson L, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of
debrisoquine. Lancet. 1993; 341:63.
24. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene
duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as
a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004; 59:803–7. [PubMed:
14652703]
25. Penas-Lledo EM, et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or
amitriptyline monotherapy treatment in major depressive patients. Molecular psychiatry. 2013;
18:8–9. [PubMed: 22733128]
26. Hodgson K, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment
response. J Psychopharmacol. 2014; 28:133–41. [PubMed: 24257813]
27. Swen JJ, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clinical
pharmacology and therapeutics. 2011; 89:662–73. [PubMed: 21412232]
28. Bertilsson L, Mellstrom B, Sjokvist F, Martenson B, Asberg M. Slow hydroxylation of
nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet.
1981; 1:560–1.
29. Shimoda K, et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline
in Japanese psychiatric patients. J Clin Psychopharmacol. 2002; 22:371–8. [PubMed: 12172336]
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.

Hicks et al.

Page 11

Author Manuscript
Author Manuscript

30. Steimer W, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6
and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Clinical chemistry. 2005; 51:376–85. [PubMed: 15590749]
31. Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of
amitriptyline and nortriptyline in the Faroese population. British journal of clinical pharmacology.
2008; 65:134–8. [PubMed: 17764479]
32. Dworkin RH, et al. Pharmacologic management of neuropathic pain: evidence-based
recommendations. Pain. 2007; 132:237–51. [PubMed: 17920770]
33. Preskorn SH, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated
for depression: implications for personalized medicine. J Clin Psychiatry. 2013; 74:614–21.
[PubMed: 23541126]
34. el-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in
patients treated with a combination of these drugs as compared with those treated with
amitriptyline alone. Journal of clinical pharmacology. 1995; 35:17–21. [PubMed: 7751409]
35. Ketter TA, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin
Psychopharmacol. 1995; 15:387–98. [PubMed: 8748427]
36. Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year
update. International journal of psychiatry in medicine. 1995; 25:277–90. [PubMed: 8567194]
37. Kim S, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016; 44:D1202–
13. [PubMed: 26400175]

Author Manuscript
Author Manuscript
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 June 20.

Hicks et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1.
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Major metabolic pathway of the tertiary amine amitriptyline and the secondary amine
nortriptyline. For the structural representation the following 2D-images from the National
Center for Biotechnology Information PubChem Compound Database are used:
amitriptyline - CID=2160 (https://pubchem.ncbi.nlm.nih.gov/compound/2160); nortriptyline
- CID=4543 (https://pubchem.ncbi.nlm.nih.gov/compound/4543); 10-hydroxyamitriptyline CID=6420900 (https://pubchem.ncbi.nlm.nih.gov/compound/6420900); 10hydroxynortriptyline - CID=6420504 (https://pubchem.ncbi.nlm.nih.gov/compound/
6420504) (37). All entries were accessed Nov. 8, 2016.
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ASSIGNMENT OF LIKELY PHENOTYPES BASED ON DIPLOTYPES
Assignment of CYP2D6 phenotypes
Likely phenotype

Activity Score

Genotypes

Examples of diplotypes

Ultrarapid metabolizer (~1–
20% of patients)a

> 2.0

An individual carrying duplications of
functional alleles

(*1/*1)xN, (*1/*2)xN, (*2/*2)xNb

Normal metabolizer (~72–
88% of patients)

1.0–2.0c

An individual carrying two normal
function alleles or two decreased
function alleles or one normal and no
function allele or one normal function
and decreased function allele or
combinations of duplicated alleles that
result in an activity score of 1.0–2.0.

*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41,
*1/*5, *1/*4

0.5

An individual carrying one decreased
function and one no function allele

*4/*41, *5/*9, *4/*10

An individual carrying only no function
alleles

*4/*4, (*4/*4)xN, *3/*4, *5/*5, *5/*6

Intermediate metabolizer
(~1–13% of patients)

Author Manuscript

Poor metabolizer (~1–10% of
patients)

0

Assignment of CYP2C19 phenotypes
Likely phenotype

Genotypes

Examples of diplotypes

Ultrarapid metabolizer (~2–5% of patients)a

An individual carrying two increased function alleles

*17/*17

Rapid Metabolizer (~2–30% of patients)

An individual carrying one normal function allele and one
increased function allele

*1/*17

Normal metabolizer (~35–50% of patients)

An individual carrying two normal function alleles

*1/*1

Intermediate metabolizer (~18–45% of patients)

An individual carrying one normal function allele and one no
function allele or one no function allele and one increased
function allele

*1/*2, *1/*3, *2/*17d

Poor metabolizer (~2–15% of patients)

An individual carrying two no function alleles

*2/*2, *2/*3, *3/*3

a

Author Manuscript

CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 (4) and CYP2D6
Frequency Tables (1) for population-specific allele and phenotype frequencies.

b

Where xN represents the number of CYP2D6 gene copies.

c

Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.

d

The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the
CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele. See Supplemental Materials for
a more comprehensive list of predicted metabolizer phenotypes.
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Increased metabolism of TCAs to less
active compounds compared to normal
metabolizers
Lower plasma concentrations of active
drug will increase probability of
pharmacotherapy failure
Normal metabolism of TCAs
Reduced metabolism of TCAs to less
active compounds compared to normal
metabolizers
Higher plasma concentrations of active
drug will increase the probability of side
effects
Greatly reduced metabolism of TCAs to
less active compounds compared to
normal metabolizers
Higher plasma concentrations of active
drug will increase the probability of side
effects

CYP2D6 Ultrarapid metabolizer

CYP2D6 Normal metabolizer

CYP2D6 Intermediate metabolizer

CYP2D6 Poor metabolizer

Strong

Moderate

Consider a 25% reduction of recommended starting dosef. Utilize
therapeutic drug monitoring to guide dose adjustmentse.

Avoid tricyclic use due to potential for side effects. Consider
alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider a 50% reduction of recommended
starting dosef. Utilize therapeutic drug monitoring to guide dose
adjustmentse.

Strong

Strong

Classification of
Recommendation
for Amitriptyline
and Nortripylinec

Initiate therapy with recommended starting dosef.

Avoid tricyclic use due to potential lack of efficacy. Consider
alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose
(compared to normal metabolizers)e. Utilize therapeutic drug
monitoring to guide dose adjustments.

Therapeutic Recommendationa,b

Optional

Optional

Strong

Optional

Classification of
Recommendation
for Other TCAsc,d
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Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steadystate dose.

f

Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.

e

It may be reasonable to apply this recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and
pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8–S16).

d

The rating scheme for the recommendation of classification is described in Supplementary Data.

c

Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial
doses are used, such as neuropathic pain.

b

For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 3 for CYP2C19-based dosing recommendations and Table 4 for CYP2D6/CYP2C19-based dosing
recommendations.

a

Implication

Phenotype

DOSING RECOMMENDATIONS FOR TRICYCLIC ANTIDEPRESSANTS BASED ON CYP2D6 PHENOTYPE
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Increased metabolism of tertiary
amines compared to normal
metabolizers
Greater conversion of tertiary
amines to secondary amines
may affect response or side
effects
Normal metabolism of tertiary
amines
Reduced metabolism of tertiary
amines compared to normal
metabolizers
Greatly reduced metabolism of
tertiary amines compared to
normal metabolizers
Decreased conversion of tertiary
amines to secondary amines
may affect response or side
effects

CYP2C19 Ultrarapid metabolizer and
CYP2C19 Rapid Metabolizer

CYP2C19 Normal metabolizer

CYP2C19 Intermediate metabolizer

CYP2C19 Poor metabolizer

Strong

Initiate therapy with recommended starting dosef.

Moderate

Strong

Initiate therapy with recommended starting dosef.

Avoid tertiary amine use due to potential for sub-optimal response.
Consider alternative drug not metabolized by CYP2C19. TCAs
without major CYP2C19 metabolism include the secondary amines
nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended
starting dosef. Utilize therapeutic drug monitoring to guide dose
adjustmentse.

Optional

Classification of
Recommendation
for Amitriptylinec

Avoid tertiary amine use due to potential for sub-optimal response.
Consider alternative drug not metabolized by CYP2C19. TCAs
without major CYP2C19 metabolism include the secondary amines
nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to
guide dose adjustmentse.

Therapeutic Recommendationa,b

Optional

Optional

Strong

Optional

Classification of
Recommendation for
Other Tertiary
Amine TCAsc,d
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Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steadystate dose.

f

e
Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.

It may be reasonable to apply this recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and
pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8–S16).

d

The rating scheme for the recommendation of classification is described in Supplementary Data.

c

Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial
doses are used, such as neuropathic pain.

b

If CYP2D6 genotype results are also available, see Table 2 for CYP2D6-based dosing recommendations and Table 4 for CYP2D6/CYP2C19-based dosing recommendations.

a

Implication

Phenotype

DOSING RECOMMENDATIONS FOR THE TERTIARY AMINES AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, AND
TRIMIPRAMINE BASED ON CYP2C19 PHENOTYPE
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CYP2C19 Poor metabolizer

Avoid amitriptyline usec
Classification of recommendationd:
Optional

Consider a 25% reduction of
recommended starting dosef,h
Classification of recommendationd:
Optional

Consider a 25% reduction of
recommended starting dosef,h
Classification of recommendationd:
Moderate

Consider alternative drug not
metabolized by CYP2C19 c,e
Classification of recommendationd:
Optional

CYP2D6 Intermediate metabolizer

Avoid amitriptyline usec
Classification of
recommendationd: Optional

Avoid amitriptyline use. If
amitriptyline is warranted,
consider a 50% reduction of
recommended starting dosef,h
Classification of
recommendationd: Optional

Avoid amitriptyline use. If
amitriptyline is warranted,
consider a 50% reduction of
recommended starting dosef,h
Classification of
recommendationd: Strong

Avoid amitriptyline usec
Classification of
recommendationd: Optional

CYP2D6 Poor metabolizer
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TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.

Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.

g

Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor
metabolism is strongly recommended.

f

e

The rating scheme for the recommendation classification is described in Supplementary Data. See CYP2D6 and CYP2C19 combined dosing recommendations for explanation of classification of
recommendations for this table.

d

If amitriptyline is warranted, utilize therapeutic drug monitoringf to guide dose adjustment.

c

The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines
to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine (the classification of this recommendation is optional).

b

Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial
doses are used, such as neuropathic pain.

a

Avoid amitriptyline use. If
amitriptyline is warranted, consider
a 50% reduction of recommended
starting dosef,h

Avoid amitriptyline usec
Classification of recommendationd:
Optional

CYP2C19 Intermediate metabolizer

Classification of recommendationd:
Moderate

Initiate therapy with recommended
starting doseh
Classification of recommendationd:
Strong

Avoid amitriptyline usec
Classification of recommendationd:
Optional

Consider alternative drug not
metabolized by CYP2C19c,e
Classification of recommendationd:
Optional

Avoid amitriptyline usec
Classification of recommendationd:
Optional
Initiate therapy with recommended
starting doseh
Classification of recommendationd:
Strong

CYP2D6 Normal metabolizer

CYP2D6 Ultrarapid metabolizer

Avoid amitriptyline use. If
amitriptyline is warranted, consider
titrating to a higher target dose
(compared to normal metabolizers)f,g
Classification of recommendationd:
Strong

CYP2C19 Normal metabolizer

CYP2C19 Ultrarapid or Rapid
metabolizer

Phenotype

DOSING RECOMMENDATIONS FOR AMITRIPTYLINE BASED ON BOTH CYP2D6 AND CYP2C19 PHENOTYPESa,b
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Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steadystate dose.
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